Lynparza Lowers Risk of Disease Progression in Advanced Ovarian Cancer, 5-year Data Show

Lynparza Lowers Risk of Disease Progression in Advanced Ovarian Cancer, 5-year Data Show
When used as a first-line therapy to treat newly diagnosed women with advanced ovarian cancer who previously responded to platinum-based chemotherapy, Lynparza (olaparib) prolonged the time they lived without showing signs of disease progression compared to a placebo, according to five-year data from a Phase 3 trial. Updated findings from the study, called SOLO-1 (NCT01844986), were presented at the recent 2020 European Society of Medical Oncology virtual congress. Lynparza is an anti-cancer therapy jointly developed by AstraZeneca and Merck (known as MSD outside the U.S. and Canada) that has been approved for the treatment of advanced ovarian cancer, pancreatic cancer, and certain types of breast cancer. The medication works by blocking an enzyme called PARP, which plays an essential role in DNA repair, and cancer cell growth and survival. Lynparza is particularly effective in patients who carry genetic mutations in BRCA genes, which are also involved in DNA repair. It was approved as a first-line maintenance therapy for women with advanced ovarian cancer whose tumors contained BRCA
Subscribe or to access all post and page content.